Steroidogenesis inhibitor ODM-209 for metastatic castration-resistant prostate cancer and advanced breast cancer: Results from the first-in-human STESIDES study

European Journal of Cancer · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles